1. |
Li MX, Liu XM, Zhang XF, et al. Prognostic role of neutrophil to lymphocyte ratio in colorectal cancer: A systematic review and meta-analysis. Int J Cancer, 2014, 134(10): 2403-2413.
|
2. |
Chau I, Cunningham D. Treatment in advanced colorectal cancer: what, when and how? Brit J Cancer, 2009, 100(11): 1704.
|
3. |
柳海霞. 中国结直肠癌诊疗规范 (2015 版). 中华普通外科学文献 (电子版), 2015, 9(6): 506-523.
|
4. |
Douillard JY, Cunningham D, Roth AD, et al. Colorectal cancer. Lancet, 2010, 375(9719): 1030-1047.
|
5. |
Banchereau J, Palucka AK. Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol, 2005, 5(4): 296.
|
6. |
Cheever MA, Higano CS. PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine. Clin Cancer Res, 2011, 17(11): 3520-3526.
|
7. |
Devitar VT, Rosenberg SA. Two hundred years of cancer research. N Engl J Med, 2012, 366(23): 2207-2214.
|
8. |
Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials, 1996, 17(1): 1-12.
|
9. |
Slim K, Nini E, Forestier D, et al. Methodological index for nonrandomized studies (MINORS): development and validation of a new instrument. Anz J Surg, 2003, 73(9): 712-716.
|
10. |
Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. J Stat Med, 2004, 23(11): 2815-2834.
|
11. |
Altman DG, Bland M. Interaction revisited: the difference between two estimates. Brit Med J, 2003, 326(7382): 219.
|
12. |
Lu D, Gu S, Du P, et al. Effect of immunotherapy on the immune function and survival of patients after colon cancer surgery. Int Clin Exp Med, 2016, 9(2): 1780-1786.
|
13. |
Gao D, Li C, Xie X, et al. Autologous tumor lysate-pulsed dendritic cell immunotherapy with cytokine-induced killer cells improves survival in gastric and colorectal cancer patients. PLoS One, 2014, 9(4): e93886.
|
14. |
Zhu H, Yang X, Li J, et al. Immune response, safety, and survival and quality of life outcomes for advanced colorectal cancer patients treated with dendritic cell vaccine and cytokine-induced killer cell therapy. Biomed Res Int, 2014, 2014: 603871.
|
15. |
Lin T, Song C, Chuo D Y, et al. Clinical effects of autologous dendritic cells combined with cytokine-induced killer cells followed by chemotherapy in treating patients with advanced colorectal cancer: a prospective study. Tumor Biol, 2016, 37(4): 4367-4372.
|
16. |
Maurel J, Caballerobanos M, Mila J, et al. Phase II randomised trial of autologous tumour lysate dendritic cell plus best supportive care compared with best supportive care in pre-treated advanced colorectal cancer patients. Eur J Cancer, 2016, 64: 167-174.
|
17. |
Du XH, Liu HL, Li L, et al. Clinical significance of immunotherapy with combined three kinds of cells for operable colorectal cancer. Tumor Biol, 2015, 36(7): 5679-5685.
|
18. |
Morse MA, Niedzwiecki D, Marshall JL, et al. A randomized phase II study of immunization with dendritic cells modified with poxvectors encoding CEA and MUC1 compared with the same poxvectors plus GM-CSF for resected metastatic colorectal cancer. Ann Surg, 2013, 258(6): 879-886.
|
19. |
应敏刚, 魏植强, 杨建伟, 等. 结直肠癌术后放化疗联合 DC-CIK 的疗效分析. 实用癌症杂志, 2010, 25(3): 274-276.
|
20. |
朱卫, 李佳丽, 张利红, 等. 自体免疫细胞治疗联合化疗治疗大肠癌的临床研究. 中国中西医结合外科杂志, 2016, 22(2): 116-119.
|
21. |
魏植强, 杨建伟, 陈路川, 等. 直肠癌术后放化疗联合 DC-CIK 回顾性疗效分析. 福建医科大学学报, 2009, 43(6): 483-487.
|
22. |
Chen W, Zheng R, Baade P D, et al. Cancer statistics in China, 2015. Ca-Cancer J Clin, 2016, 66(2): 115-132.
|
23. |
Riedy M. Preventing colorectal cancer. Adv NPs Pas, 2013, 4(6): 18-21.
|
24. |
De ICL, Henao CF, Vicente BD, et al. Immune microenvironment in colorectal cancer: a new hallmark to change old paradigms. Clin Dev Immuno, 2011, 2011: 174149.
|
25. |
Rybojad P, Jabłonka A, Wilczyńska B, et al. Surgery decreases number of cells secreting cytotoxic mediators and increases secretion of interleukin 10 in patients with lung cancer. Eur J Surg Oncol, 2013, 39(11): 1269-1277.
|
26. |
Feig C, Jones J O, Kraman M, et al. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti–PD-L1 immunotherapy in pancreatic cancer. Proc Natl Acad Sci USA, 2013, 110(50): 20212-20217.
|
27. |
Mace TA, Ameen Z, Collins A, et al. Pancreatic cancer-associated stellate cells promote differentiation of myeloid-derived suppressor cells in a STAT3-dependent manner. Cancer Res, 2013, 73(10): 3007-3018.
|
28. |
Lambert LA, Gibson GR, Maloney M, et al. Intranodal immunization with tumor lysate-pulsed dendritic cells enhances protective antitumor immunity. Cancer Res, 2001, 61(2): 641-646.
|
29. |
Irvine KR, Parkhurst MR, Shulman EP, et al. Recombinant virus vaccination against “self” antigens using anchor-fixed immunogens. Cancer Res, 1999, 59(11): 2536-2540.
|
30. |
Toes RE, Ei VDV, Schoenberger SP, et al. Enhancement of tumor outgrowth through CTL tolerization after peptide vaccination is avoided by peptide presentation on dendritic cells. J Immunol, 1998, 160(9): 4449-4456.
|
31. |
瞿霏霏, 黄伟谦, 张闯, 等. 树突状细胞疫苗联合射频消融术治疗结直肠癌肝转移临床疗效. 中国肿瘤生物治疗杂志, 2016, 23(1): 73-78.
|
32. |
Günther K, Radkow T, Reymond M A, et al. Angiogenesis and dendritic cell density are not correlated with metachronous distant metastasis in curatively operated rectal cancer. Int J Colorectal Dis, 2003, 18(4): 300-308.
|
33. |
Shapira S, Lisiansky V, Arber N, et al. Targeted immunotherapy for colorectal cancer: monoclonal antibodies and immunotoxins. Expert Opin Inv Drug, 2010, 19(Sup1): S67-S77.
|
34. |
Dougan M, Dranoff G. Immune therapy for cancer. Annu Rev Immunol, 2009, 27(27): 83-117.
|
35. |
Sangiolo D, Martinuzzi E, Todorovic M, et al. Alloreactivity and anti-tumor activity segregate within two distinct subsets of cytokine-induced killer (CIK) cells: implications for their infusion across major HLA barriers. Int Immunol, 2008, 20(7): 841-848.
|
36. |
Zhang G, Zhao H, Wu J, et al. Adoptive immunotherapy for non-small cell lung cancer by NK and cytotoxic T lymphocytes mixed effector cells: retrospective clinical observation. Int Immunopharmacol, 2014, 21(2): 396-405.
|
37. |
Introna M, Golay J, Rambaldi A. Cytokine Induced Killer (CIK) cells for the treatment of haematological neoplasms. Immunol Lett, 2013, 155(1): 27-30.
|
38. |
Okada N. Cell delivery system: a novel strategy to improve the efficacy of cancer immunotherapy by manipulation of immune cell trafficking and biodistribution. Biol Pharm Bull, 2005, 28(9): 1543-1550.
|
39. |
Lu PH, Negrin RS. A novel population of expanded human CD3+CD56+cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. J Immunol, 1994, 153(4): 1687-1696.
|
40. |
Margolin KA, Negrin RS, Wong KK, et al. Cellular immunotherapy and autologous transplantation for hematologic malignancy. Immunol Rev, 1997, 157(1): 231-240.
|